ALOX15 regulation of colon cancer invasiveness via PI3P-linoleic acid metabolism
ALOX15 通过 PI3P-亚油酸代谢调节结肠癌侵袭性
基本信息
- 批准号:10545078
- 负责人:
- 金额:$ 63.89万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-01-01 至 2026-12-31
- 项目状态:未结题
- 来源:
- 关键词:ALOX15 geneAPC mutationAcidsAdenocarcinomaAdverse eventAffectAmerican dietAnimalsArachidonate 15-LipoxygenaseAutomobile DrivingAzoxymethaneBenignBiological AssayBiological MarkersBreedingCD44 geneCDX2 geneCancer EtiologyCell membraneCellular MembraneCessation of lifeChemicalsChemopreventive AgentColonColon CarcinomaColonic PolypsColorectalColorectal CancerComplexConsumptionCorn OilCyclin D1DNA Sequence AlterationDataDevelopmentDietDiseaseDoxycyclineEndosomesEnzymesEventGenesGoalsHumanImmunodeficient MouseIn VitroIncidenceInduced MutationIntakeIntegration Host FactorsInterventionInvadedKRAS2 geneKRASG12DKnowledgeLDL-Receptor Related Protein 1LGR5 geneLentivirusLinoleic AcidsLipoxygenase 1Liquid ChromatographyLoxP-flanked alleleMass Spectrum AnalysisMetabolismMucous MembraneMusMutationOmega-6 Fatty AcidsOrganoidsPhospholipidsPolyunsaturated Fatty AcidsPrevention strategyRecyclingRegulationReportingResearchResectedResolutionRiskRodentRoleSamplingSignal TransductionSystemTestingTissuesTransfectionTransgenic OrganismsUnited Statesadenomaaldehyde dehydrogenase 1beta cateninc-myc Genescancer invasivenesscarcinogenesiscolon cancer riskcolon carcinogenesisdietarydietary excessdrinking watergain of functionin vivoinsightlipoprotein receptor related protein 5loss of functionmouse modelnovelnovel chemopreventionorganoid transplantationpermissivenessperoxidationphosphatidylinositol 3-phosphatepreventpreventive interventionreceptorstem cell self renewalstem cellsstemnesstherapy developmenttumortumorigenesisvillin
项目摘要
Colorectal cancer is the third leading cause of cancer deaths in the United States. The long-term goal of our
research is to develop novel interventions to prevent colorectal carcinogenesis (CRC). CRC invasiveness, a
critical adverse step during CRC progression, requires a combination of certain genetic mutations (e.g. APC,
KRAS and Trp53 mutations), which are the key events to drive CRC. However, CRC progression also requires
additional factors which increase aberrant Beta-catenin (B-catenin) activation above levels induced by APC/B-
catenin mutations. Linoleic acid (LA), the most commonly consumed omega-6 polyunsaturated fatty acids in
humans, increases both chemically (AOM)– and APC mutation– induced CRC tumorigenesis in mice.
Nonetheless, human studies have been inconclusive regarding the impact of dietary LA on CRC. Determination
of LA's role in CRC is important because American diets are enriched with LA while expression of the main
metabolizing enzyme for LA,15-lipoxygenase-1 (ALOX15), is lost in human CRC. Recently, we found that 1)
high dietary levels of LA promoted CRC by increasing phosphatidylinositol 3-phosphate (PI3P) containing LA
(PI3P_LA), which increases LRP5 membranous recycling and subsequently B-catenin activation; 2) ALOX15-
induced conversion of PI3P_LA to PI3P_13-HODE suppresses; LRP5 membranous recycling, B-catenin
activation, CRC stemness and LA promotion of CRC, especially formation of large tumors, associated with CRC
invasiveness; 3) ALOX15 loss of function (LOF) promotes large CRC tumor formation by azoxymethane in
12/15LOX-KO-12LOX (ALOX15-LOF) mice. Whether loss of ALOX15 expression promotes CRC invasiveness
remains unknown. Our preliminary data show that ALOX15-LOF mice increased CRC invasiveness and targeted
APC mutation into Lgr5+ colorectal stem cells induced CRC in the mice, which was blocked by transgenic
ALOX15 expression. We therefore hypothesize that ALOX15 loss of function promotes CRC invasiveness by
increasing PI3P_LA levels, which enhances LRP5 membranous recycling, thus potentiating Wnt/B-catenin
signaling and subsequently stemness. Aim 1 will determine the effects of ALOX15 gain of function and ALOX15
LOF on LRP5, B-catenin activation, CRC stemness and invasiveness using CRC mouse models in which CRC
invasiveness is promoted by either a combination of APC, KRASG12D and Trp53R172H mutations or Trp53R172H
mutation with AOM induced B-catenin and KRAS mutations. Aim 2 will determine the effects of ALOX15 LOF
on PI3P-LA, LRP5, B-catenin activation, stemness and invasiveness in human CRCs and examine the effects
of ALOX15 re-expression via lentivirus Tet-on inducible system in human CRC-derived organoids on
invasiveness in-vitro and in-vivo studies. The proposed studies are expected to provide important mechanistic
insights into whether colonic ALOX15 expression as a host factor affects CRC invasiveness risk especially with
high dietary LA intake. This gained knowledge could inform subjects with colorectal ALOX15 LOF to avoid high
LA intake and spur development of interventions to target ALOX15 for re-expression to prevent invasive CRC.
结直肠癌是美国第三大癌症死亡原因。我们的长期目标是。
研究的目的是开发新的干预措施来预防结直肠癌(CRC)的侵袭性。
CRC 进展过程中的关键不利步骤,需要某些基因突变的组合(例如 APC、
KRAS 和 Trp53 突变),这是驱动 CRC 的关键事件,然而,CRC 的进展也需要。
导致异常 β-连环蛋白 (B-连环蛋白) 激活高于 APC/B- 诱导水平的其他因素
连环蛋白突变。亚油酸 (LA),最常见的 omega-6 多不饱和脂肪酸。
人类,增加了化学(AOM)和 APC 突变诱导的小鼠 CRC 肿瘤发生。
然而,关于膳食 LA 对 CRC 测定的影响尚无定论。
了解 LA 在 CRC 中的作用非常重要,因为美国饮食中富含 LA,而主要表达
LA 代谢酶 15-脂氧合酶-1 (ALOX15) 在人类 CRC 中缺失。最近,我们发现 1)
高膳食水平的 LA 通过增加含有 LA 的磷脂酰肌醇 3-磷酸 (PI3P) 来促进结直肠癌
(PI3P_LA),增加 LRP5 膜回收和随后的 B-连环蛋白激活;2) ALOX15-
诱导 PI3P_LA 转化为 PI3P_13-HODE 抑制 LRP5 膜回收;B-连环蛋白
CRC 的激活、CRC 干性和 LA 促进 CRC,特别是与 CRC 相关的大肿瘤的形成
侵袭性;3) ALOX15 功能丧失 (LOF) 通过氧化偶氮甲烷促进大结直肠癌肿瘤形成
12/15LOX-KO-12LOX (ALOX15-LOF) 小鼠。ALOX15 表达缺失是否会促进 CRC 侵袭性。
我们的初步数据表明 ALOX15-LOF 小鼠增加了 CRC 侵袭性和靶向性。
APC 突变为 Lgr5+ 结直肠干细胞可诱导小鼠结直肠癌,但转基因可阻断该现象
因此,我们认为 ALOX15 功能丧失会通过以下方式促进 CRC 侵袭。
增加 PI3P_LA 水平,从而增强 LRP5 膜回收,从而增强 Wnt/B-catenin
信号传导和随后的干细胞性将确定 ALOX15 功能增益和 ALOX15 的影响。
使用 CRC 小鼠模型对 LRP5、B-连环蛋白激活、CRC 干性和侵袭性进行 LOF,其中 CRC
APC、KRASG12D 和 Trp53R172H 突变的组合或 Trp53R172H 会促进侵袭性
AOM 诱导的 B-连环蛋白和 KRAS 突变的突变目标 2 将确定 ALOX15 LOF 的影响。
对人类 CRC 中 PI3P-LA、LRP5、B-catenin 激活、干性和侵袭性的影响并检查其影响
通过慢病毒 Tet-on 诱导系统在人 CRC 衍生的类器官中重新表达 ALOX15
拟议的研究预计将提供重要的机制。
深入了解结肠 ALOX15 表达作为宿主因素是否会影响 CRC 侵袭风险,尤其是
饮食中 LA 的高摄入量可以帮助患有结直肠 ALOX15 LOF 的受试者避免高剂量的 LA 摄入。
LA 摄入并刺激针对 ALOX15 重新表达的干预措施的开发,以预防侵袭性 CRC。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Imad Shureiqi其他文献
Imad Shureiqi的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Imad Shureiqi', 18)}}的其他基金
ALOX15 regulation of colon cancer invasiveness via PI3P-linoleic acid metabolism
ALOX15 通过 PI3P-亚油酸代谢调节结肠癌侵袭力
- 批准号:
10339182 - 财政年份:2022
- 资助金额:
$ 63.89万 - 项目类别:
15-LOX-1 Modulation of Colon Cancer Promotion by Linoleic Acid
亚油酸对 15-LOX-1 促进结肠癌的调节
- 批准号:
10330050 - 财政年份:2021
- 资助金额:
$ 63.89万 - 项目类别:
15-LOX-1 Regulation of Resolving Generation to Modulate Colon Cancer
15-LOX-1 调节分解生成以调节结肠癌
- 批准号:
9980183 - 财政年份:2016
- 资助金额:
$ 63.89万 - 项目类别:
15-LOX-1 Regulation of Resolving Generation to Modulate Colon Cancer
15-LOX-1 调节分解生成以调节结肠癌
- 批准号:
9187612 - 财政年份:2016
- 资助金额:
$ 63.89万 - 项目类别:
15-LOX-1 Modulation of Colon Cancer Promotion by Linoleic Acid
亚油酸对 15-LOX-1 促进结肠癌的调节
- 批准号:
9886073 - 财政年份:2016
- 资助金额:
$ 63.89万 - 项目类别:
15-LOX-1 regulation of resolving generation to modulate colon cancer
15-LOX-1 调节分解生成以调节结肠癌
- 批准号:
10301423 - 财政年份:2016
- 资助金额:
$ 63.89万 - 项目类别:
Molecular targeting of PPAR-delta in colon cancer
结肠癌中 PPAR-δ 的分子靶向
- 批准号:
8259197 - 财政年份:2010
- 资助金额:
$ 63.89万 - 项目类别:
Molecular targeting of PPAR-delta in colon cancer
结肠癌中 PPAR-δ 的分子靶向
- 批准号:
8091356 - 财政年份:2010
- 资助金额:
$ 63.89万 - 项目类别:
Molecular targeting of PPAR-delta in colon cancer
结肠癌中 PPAR-δ 的分子靶向
- 批准号:
8452733 - 财政年份:2010
- 资助金额:
$ 63.89万 - 项目类别:
Molecular targeting of PPAR-delta in colon cancer
结肠癌中 PPAR-δ 的分子靶向
- 批准号:
7987654 - 财政年份:2010
- 资助金额:
$ 63.89万 - 项目类别:
相似国自然基金
APC15突变导致卵母细胞减数分裂阻滞的分子机制研究
- 批准号:82371661
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
APC突变促进m6A甲基转移酶METTL3依赖性转录调控以诱导结直肠癌免疫逃逸的机制研究
- 批准号:
- 批准年份:2022
- 资助金额:30 万元
- 项目类别:青年科学基金项目
KDEL受体蛋白抑制APC/C-Cdh1负调控GLS介导IDH突变型胶质瘤耐药的机制研究
- 批准号:
- 批准年份:2021
- 资助金额:55 万元
- 项目类别:面上项目
靶向TNKS-USP25互作新抗霉素类天然活性分子的结构优化及抗APC/KRAS突变结直肠癌作用机制研究
- 批准号:
- 批准年份:2020
- 资助金额:55 万元
- 项目类别:面上项目
同义突变调控APC蛋白生物学功能及结直肠癌的发生发展
- 批准号:32000539
- 批准年份:2020
- 资助金额:24 万元
- 项目类别:青年科学基金项目
相似海外基金
ALOX15 regulation of colon cancer invasiveness via PI3P-linoleic acid metabolism
ALOX15 通过 PI3P-亚油酸代谢调节结肠癌侵袭力
- 批准号:
10339182 - 财政年份:2022
- 资助金额:
$ 63.89万 - 项目类别:
Task Order: Colorectal Cancer Prevention by a Novel EPA Analogue TP-252 and Naproxen in FAP and lynch syndrome models
任务顺序:通过新型 EPA 类似物 TP-252 和萘普生在 FAP 和林奇综合征模型中预防结直肠癌
- 批准号:
10349404 - 财政年份:2019
- 资助金额:
$ 63.89万 - 项目类别:
Regulatory T Cell Control of Intestinal Tumorigenesis
肠道肿瘤发生的调节性 T 细胞控制
- 批准号:
9379022 - 财政年份:2014
- 资助金额:
$ 63.89万 - 项目类别:
Nanotheranostics for Early Colorectal Cancer Detection and Treatment
用于早期结直肠癌检测和治疗的纳米治疗学
- 批准号:
9230348 - 财政年份:2013
- 资助金额:
$ 63.89万 - 项目类别:
Nanotheranostics for Early Colorectal Cancer Detection and Treatment
用于早期结直肠癌检测和治疗的纳米治疗学
- 批准号:
9015793 - 财政年份:2013
- 资助金额:
$ 63.89万 - 项目类别: